Pediatric Review Committee
Executive Summary
An internal panel of experts will provide advice on pediatric studies and exclusivities, FDA announces Oct. 25. Plans to have the new Pediatric Review Committee look over all written requests for pediatric studies prior to their issuance could help the agency define more precisely the studies it wants industry to perform (1"The Pink Sheet" July 2, 2007, p. 8). PeRC, which will be composed of representatives from CDER, CBER and the Commissioner's Office and will initially meet weekly, will also analyze the agency's past performance in implementing provisions of the Pediatric Research Equity Act concerning assessments of a drug's efficacy and safety in the pediatric population...
You may also be interested in...
Pediatric Data Submissions: FDA Tips For Navigating Committee Review
Drug sponsors need to be pro-active and thorough in justifying their approach to pediatric studies in light of the added layer of review now conducted by the internal FDA Pediatric Review Committee, FDA's Lisa Mathis advised at the DIA annual meeting in Boston June 25
Pediatric Study Requests Would Benefit From Input On Trial Design – Cmte.
FDA hopes that internal process improvements will result in "more clever" requests to companies for pediatric studies under the Best Pharmaceuticals for Children Act
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.